125
Participants
Start Date
May 31, 2009
Primary Completion Date
September 30, 2011
Study Completion Date
December 31, 2013
Epic™ Nitinol Stent System
The Epic™ Nitinol Stent System is comprised of two components: the implantable nitinol endoprosthesis and the stent delivery system.
Anti-platelet therapy
Investigators must prescribe concomitant anti-platelet medication consistent with current clinical practice. Anti-platelet therapy should be administered preprocedure and continued throughout participation in the trial.
Anti-coagulation therapy
Anti-coagulation therapy must be administered during the procedure consistent with current clinical practice.
Mount Sinai Medical Center, New York
UPMC - Shadyside Hospital, Pittsburgh
York Hospital, York
Wake Medical Center, Raleigh
Mid-Carolina Cardiology - Presbyterian Hospital, Charlotte
Piedmont Hospital, Atlanta
Holy Cross Hospital, Fort Lauderdale
Brandon Regional Hospital, Brandon
Mediquest Research at Munroe Regional Medical Center, Ocala
St. Thomas Research Institute, Nashville
Erlanger Medical Center, Chattanooga
Ohio State University Medical Center, Columbus
Grant Medical Center, Columbus
Cleveland Clinic, Cleveland
St. Vincent's Hospital, Indianapolis
Wellstar Kennestone Hospital, Marietta
Parkview Hospital-Parkview Research Center, Fort Wayne
University of Michigan, Ann Arbor
Trinity Terrace Park, Davenport
North Memorial Medical Center, Robbinsdale
MeritCare Hospital, Fargo
Advocate Christ Medical Center, Oak Lawn
University of Oklahoma Health Science Center, Oklahoma City
VA North Texas Health Care System, Dallas
Baptist Hospital of San Antonio, San Antonio
St. Joseph's Hospital, Tucson
Rhode Island Hospital, Providence
Fletcher Allen Health Care, Burlington
Lead Sponsor
Boston Scientific Corporation
INDUSTRY